Literature DB >> 9227580

Adrenomedullin microinjection into the area postrema increases blood pressure.

M A Allen1, P M Smith, A V Ferguson.   

Abstract

Adrenomedullin (ADM) circulates in the blood at concentrations comparable to other vasoactive peptides with established roles in cardiovascular regulation. Intravenously administered ADM produces a clear hypotensive effect, whereas intracerebroventricular microinjections result in increases in blood pressure (BP). Recently, we demonstrated that ADM influences neurons of the area postrema (AP), a central nervous system site implicated in cardiovascular control. However, to address directly the physiological significance of the actions of ADM at the AP, an in vivo microinjection study was undertaken. ADM, at two concentrations (1 and 10 microM), in volumes of 50, 100, and 200 nl, was microinjected into the AP or NTS of 21 urethan-anesthetized male Sprague-Dawley rats. Microinjection of 10 microM ADM (100 nl) resulted in significant transient (2-5 min) increases in BP [120 s area under the curve (AUC): 684.3 +/- 268.6 mmHg/s (P < 0.05)], and heart rate (HR) [AUC: 12.5 +/- 4.5 beats/min (P < 0.05)]. The lower concentration of ADM (1 microM) had no effect on either BP (179.1 +/- 143.6 mmHg/s) or HR (0.8 +/- 2.6 beats/min). ADM was also microinjected into the immediately adjacent nucleus of the solitary tract, where it was found to be without effect on either BP or HR. This study demonstrates, for the first time, a physiological role for ADM acting at a specific brain site, the AP, to produce significant cardiovascular responses.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9227580     DOI: 10.1152/ajpregu.1997.272.6.R1698

Source DB:  PubMed          Journal:  Am J Physiol        ISSN: 0002-9513


  9 in total

1.  The distribution of mast cells in the human area postrema.

Authors:  Andrea Porzionato; Veronica Macchi; Anna Parenti; Raffaele De Caro
Journal:  J Anat       Date:  2004-02       Impact factor: 2.610

2.  Microvascular patterns in human medullary tegmentum at the level of the area postrema.

Authors:  Andrea Porzionato; Veronica Macchi; Leonardo Morsut; Anna Parenti; Raffaele De Caro
Journal:  J Anat       Date:  2005-04       Impact factor: 2.610

Review 3.  Novel neurohumoral factors in congestive heart failure: adrenomedullin.

Authors:  J G Lainchbury
Journal:  Curr Cardiol Rep       Date:  2001-05       Impact factor: 2.931

4.  Adrenomedullin in the rostral ventrolateral medulla inhibits baroreflex control of heart rate: a role for protein kinase A.

Authors:  Yong Xu; Teresa L Krukoff
Journal:  Br J Pharmacol       Date:  2006-05       Impact factor: 8.739

5.  Mid-regional-pro-adrenomedullin plasma levels are increased in obese adolescents.

Authors:  Silvia Del Ry; Manuela Cabiati; Vanessa Bianchi; Laura Caponi; Pietro Di Cecco; Benedetta Marchi; Emioli Randazzo; Chiara Caselli; Tommaso Prescimone; Aldo Clerico; Giovanni Federico
Journal:  Eur J Nutr       Date:  2015-05-29       Impact factor: 5.614

6.  Adrenomedullin in the rostral ventrolateral medulla increases arterial pressure and heart rate: roles of glutamate and nitric oxide.

Authors:  Yong Xu; Teresa L Krukoff
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2004-06-03       Impact factor: 3.619

7.  Decrease in arterial pressure induced by adrenomedullin in the hypothalamic paraventricular nucleus is mediated by nitric oxide and GABA.

Authors:  Yong Xu; Teresa L Krukoff
Journal:  Regul Pept       Date:  2004-06-15

8.  Increased apelin receptor gene expression in the subfornical organ of spontaneously hypertensive rats.

Authors:  Philip R Griffiths; Stephen J Lolait; Aarifah Bijabhai; Aoife O'Carroll-Lolait; Julian F R Paton; Anne-Marie O'Carroll
Journal:  PLoS One       Date:  2020-04-21       Impact factor: 3.240

Review 9.  Donor Human Milk: Effects of Storage and Heat Treatment on Oxidative Stress Markers.

Authors:  Enrico Bertino; Chiara Peila; Francesco Cresi; Elena Maggiora; Stefano Sottemano; Diego Gazzolo; Sertac Arslanoglu; Alessandra Coscia
Journal:  Front Pediatr       Date:  2018-10-05       Impact factor: 3.418

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.